NCT00413790

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 162 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: —

Summary

This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Darifenacin	Darifenacin tablets 15 mg once daily
DRUG	Tolterodine	Tolterodine extended release (ER) 4 mg once daily
DRUG	Placebo	Placebo tablet once daily

Timeline

• Start date: 2006-11-01
• Completion: 2007-09-01
• First posted: 2006-12-20
• Last updated: 2008-01-15

Locations

12 sites across 1 country: United States